Tianshu Pharmaceutical Ranks Among "Top 20 China Pharmaceutical CDMO Enterprises"

　On June 20, the "2025 PDI Pharmaceutical R&D · Innovation Conference and China Pharmaceutical R&D Top 100 List Launch Event" grandly announced the "2025 China Pharmaceutical R&D Strength Ranking Series Lists". Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical) ranked among the "Top 20 China Pharmaceutical CDMO Enterprises" list.

　　The "Top 20 China Pharmaceutical CDMO Enterprises 2025" list is selected strictly based on 10 indicators: annual total revenue (operating total revenue), annual revenue growth, net profit, net profit growth, R&D investment, R&D investment growth, personnel scale, personnel scale growth, brand awareness, and leading enterprise in segmented fields, representing the highest level of China's pharmaceutical CDMO industry. Tianshu Pharmaceutical was honored to be on the list for the first time, fully demonstrating that the company's comprehensive strength has been highly recognized by industry leaders and peers.

Tianshu Pharmaceutical has always adhered to innovation-driven development, taking creating value for customers as its responsibility, differentiated technology as the core, advanced manufacturing as the orientation, and quality system as the guarantee. It wholeheartedly provides innovative drug CDMO, high-end API, and advanced pharmaceutical intermediate supply services for global pharmaceutical companies and new drug R&D institutions, covering efficient, flexible, and high-quality one-stop CDMO solutions throughout the drug life cycle. Tianshu Pharmaceutical continues to build differentiated technologies and has realized the industrial production of drugs with high technical barriers and continuous multi-step complex processes. At the same time, it actively explores greener, safer, and more intelligent advanced engineering technologies in the biomedical field, such as continuous flow, micro-packed bed, metal catalysis, and bioenzyme catalysis, to continuously provide more efficient, high-quality, and low-cost products and services for customers.

　　In the future, Tianshu Pharmaceutical will continue to strengthen the construction of one-stop drug R&D and production service platforms, actively build an open cooperation platform and win-win ecosystem for global pharmaceutical companies, and contribute "Tianshu strength" to the innovative development of the pharmaceutical industry.